Boehringer Ingelheim struck a potential $1B multi-year collaboration with Envisagenics, centered on the company’s RNA splicing platform (SpliceCore) to identify tumor-specific targets. The deal covers target validation across modalities including antibody-drug conjugates, T-cell engagers, and multispecific antibodies, with Boehringer receiving the option to exclusively license selected targets after the research program. Separately, Envisagenics also became the subject of a deal-focused market read-through after reporting investor interest driven by its platform economics and non-dilutive funding potential. For drug developers, the pact underscores how alternative RNA processing is being treated as a scalable source of oncology target differentiation.